IP Library › Granted Patent US 11,806,380
Granted Patent B2
US 11,806,380 · App. 17/834,215 · Granted Nov 7, 2023

Method and composition for preventing and treating COVID-19 and long COVID

Inventors: Mei-Nan Tuan (Taipei, TW); Hien Ly Doan (Taipei, TW); Zi-Yi Huang (Kaohsiung, TW); Chia-Yin Lee (Douliu, TW); Thuc Anh Nguyen (Taipei, TW)
Assignee: GLOBAL PREVENTIVE MEDICINE BIOTECH COMPANY LIMITED
A61K36/82A61K31/05A61K31/352A61K31/353A61K31/7048A61K31/716A61K36/185A61K36/28A61K36/48A61K36/63A61K36/87A61P31/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,806,380
App. No.
17/834,215
Granted
Nov 7, 2023
Kind
B2
Abstract

Coronavirus Disease 2019 (COVID-19) remains a threat with the emergence of new variants, especially Delta and Omicron, without specific effective therapeutic drugs. The present invention provides a method and a composition for preventing and treating COVID-19 (SARS-CoV-2) coronavirus infection which includes administering to a subject in need thereof one or more therapeutically effective doses of Virofree which comprises a pharmaceutically acceptable combination of grape seed extract, acerola cherry extract, olive leaf extract, marigold extract, green tea extract, pomegranate extract, yeast beta-glucan and soya bean extract for a treatment period.

Claims (4)

1. A capsule consisting essentially of a grape seed extract, an acerola cherry extract, an olive leaf extract, a marigold extract, a green tea extract, a pomegranate extract, a yeast beta-glucan and a soybean extract.

2. The capsule of claim 1 , consisting essentially of 10 wt %-50 wt % of the grape seed extract, 5 wt %-30 wt % of the acerola cherry extract, 5 wt %-30 wt % of the olive leaf extract, 1 wt %-20 wt % of the marigold extract, 1 wt %-20 wt % of the green tea extract, 1 wt %-20 wt % of the pomegranate extract, 1 wt %-20 wt % of the yeast beta-glycan, and 1 wt %-20 wt % of the soybean extract, based on the total weight of the capsule.

3. The capsule of claim 1 , wherein the capsule consists essentially of about 250 mg grape seed extract, about 180 mg acerola cherry extract, about 160 mg olive leaf extract, about 90 mg marigold extract, about 80 mg green tea extract, about 80 mg pomegranate extract, about 80 mg yeast beta-glycan and about 80 mg soybean extract.

4. The capsule of claim 1 , wherein the capsule consists essentially of about 25% grape seed extract, about 18% acerola cherry extract, about 16% olive leaf extract, about 9% marigold extract, about 8% green tea extract, about 8% pomegranate extract, about 8% yeast beta-glycan, and about 8% soybean extract, based on the total weight of the capsule.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 24, 2022
From: TUAN, MEI-NAN; DOAN, HIEN LY; HUANG, ZI-YI; LEE, CHIA-YIN; NGUYEN, THUC ANH
To: GLOBAL PREVENTIVE MEDICINE BIOTECH COMPANY LIMITED
Reel/Frame 060881/0134 →
Continuity (3)
Provisional Application 63277774 · Nov 10, 2021
Provisional Application 63197701 · Jun 7, 2021
Related Publication 20220387541A1 · Dec 8, 2022